What is the quality of evidence for ACE-inhibitor high dose versus low dose (CKD stages 3b-4) in regards to all-cause mortality?
The quality of evidence for ACE-inhibitor high dose versus low dose (CKD stages 3b-4) in regards to all-cause mortality is VERY LOW due to risk of bias, indirectness. Data was insufficient to calculate control group, but the overall risk for the CKD group was from 52 fewer to 69 more.